Cynerio (now Axonius Healthcare)
Device Security PlatformsHTMwire assessment
IoMT security platform with auto-generated microsegmentation policies, device utilization analytics, and compliance reporting for healthcare.
Key Features
- ✓ Auto-generated microsegmentation policies with virtual testing before deployment
- ✓ Deep packet inspection for passive device discovery and classification
- ✓ IoT Attack Detection and Response module with quarantine capability
- ✓ Customizable compliance reporting for TJC, HICP, DSPT, and other standards
- ✓ Device utilization and optimization analytics
What It Helps You Do
What Sets Them Apart
Only IoMT platform that generates microsegmentation policies and tests them in a virtual environment before deployment — reduces risk of network disruptions during implementation.
How Cynerio (now Axonius Healthcare) Uses AI
HTMwire's independent read on the technology — not the vendor's marketing claim.
Uses ML for device behavioral anomaly detection and attack identification, combined with threat intelligence feeds. Automated risk scoring leverages EPSS and CVSS for prioritization based on exploitation likelihood.
- Behavioral anomaly detection. Learns device behavior to detect anomalies and identify attacks, combined with threat-intelligence feeds.
- Exploit-likelihood risk scoring. Automated risk scoring uses EPSS and CVSS to prioritize vulnerabilities by likelihood of exploitation.
Key Numbers
- ▪ Acquired by Axonius (2025) for more than $100M
- ▪ ~$37M raised pre-acquisition; $30M Series B (2021)
Integrations
Tags
Trust Signals
Frequently Asked Questions
Is Cynerio still independent or was it acquired?
Cynerio was acquired by cybersecurity firm Axonius in mid-2025 in a cash-and-stock deal reported at more than $100M (some Israeli reports cited up to $180M, with earn-outs potentially reaching $250M). Its medical-device security capability now sits within Axonius Healthcare.
How does Cynerio detect threats to medical devices?
Cynerio uses deep packet inspection for passive device discovery and applies device behavioral anomaly detection combined with threat intelligence, with risk scoring leveraging EPSS and CVSS to prioritize by exploitation likelihood.
Who founded Cynerio?
Cynerio was founded by CEO Leon Lerman and CTO Daniel Brodie, both veterans of the Israeli IDF's Unit 8200, and was headquartered in New York.
How was Cynerio funded before the acquisition?
Cynerio raised about $37M, including a $7M seed round (2019) and a $30M Series B (2021) led by the ALIVE Israel HealthTech Fund, with backing from Rafael Development Corporation and Elron Ventures.
Sources
- SecurityWeek: Axonius acquires Cynerio in $100M+ deal
- Calcalist/CTech: Axonius-Cynerio deal, founders Leon Lerman & Daniel Brodie
- MPO: Cynerio raises $30M Series B (ALIVE Israel HealthTech Fund)
We cite a primary or named source for every claim on this page. How we evaluate →